Ensuring Uptake of Vaccines against SARS-CoV-2

Silverman, Ross D.; Omer, Saad B.

doi:10.1056/nejmp2020926

Cited by 83 publications

(98 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

“…Although mandating vaccine uptake may be considered as an approach for ensuring herd immunity against COVID-19, certain criteria should be fulfilled before such a policy is put in place ( 85 ). One of these include that the Advisory Committee overseeing immunization practices has recommended certain high-risk groups such as the elderly or health-care workers for mandatory vaccines ( 85 ). Some other criteria include evidence that COVID-19 is not effectively contained in the region, evidence that information about the vaccine's safety and efficacy is communicated to the public in a transparent manner, presence of adequate supply of the vaccine and evidence that not enough members of high-risk groups are taking the vaccine voluntarily ( 85 ).…”

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

“…One of these include that the Advisory Committee overseeing immunization practices has recommended certain high-risk groups such as the elderly or health-care workers for mandatory vaccines ( 85 ). Some other criteria include evidence that COVID-19 is not effectively contained in the region, evidence that information about the vaccine's safety and efficacy is communicated to the public in a transparent manner, presence of adequate supply of the vaccine and evidence that not enough members of high-risk groups are taking the vaccine voluntarily ( 85 ). Lastly, should an adverse reaction to a vaccine occur, programs should be in place to ensure that there is compensation provided to these individuals and that a record is kept of adverse events to re-evaluate safety ( 85 ).…”

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

“…Some other criteria include evidence that COVID-19 is not effectively contained in the region, evidence that information about the vaccine's safety and efficacy is communicated to the public in a transparent manner, presence of adequate supply of the vaccine and evidence that not enough members of high-risk groups are taking the vaccine voluntarily ( 85 ). Lastly, should an adverse reaction to a vaccine occur, programs should be in place to ensure that there is compensation provided to these individuals and that a record is kept of adverse events to re-evaluate safety ( 85 ). With these criteria, responsible authorities should ensure that an effective and fair policy is in place such that if the need for mandatory vaccine is deemed necessary, public trust in the health care system is not jeopardized.…”

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

See 3 more Smart Citations

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

et al. 2020

View full text Add to dashboard Cite

A novel coronavirus, which has been designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in December 2019 in Wuhan China and causes the highly infectious disease referred to as COVID-19. COVID-19 has now spread worldwide to become a global pandemic affecting over 24 million people as of August 26th, 2020 and claimed the life of more than 800,000 people worldwide. COVID-19 is asymptomatic for some individuals and for others it can cause symptoms ranging from flu-like to acute respiratory distress syndrome (ARDS), pneumonia and death. Although it is anticipated that an effective vaccine will be available to protect against COVID-19, at present the world is relying on social distancing and hygiene measures and repurposed drugs. There is a worldwide effort to develop an effective vaccine against SARS-CoV-2 and, as of late August 2020, there are 30 vaccines in clinical trials with over 200 in various stages of development. This review will focus on the eight vaccine candidates that entered Phase 1 clinical trials in mid-May, including AstraZeneca/Oxford's AZD1222, Moderna's mRNA-1273 and Sinovac's CoronaVac vaccines, which are currently in advanced stages of vaccine development. In addition to reviewing the different stages of vaccine development, vaccine platforms and vaccine candidates, this review also discusses the biological and immunological basis required of a SARS-CoV-2 vaccine, the importance of a collaborative international effort, the ethical implications of vaccine development, the efficacy needed for an immunogenic vaccine, vaccine coverage, the potential limitations and challenges of vaccine development. Although the demand for a vaccine far surpasses the production capacity, it will be beneficial to have a limited number of vaccines available for the more vulnerable population by the end of 2020 and for the rest of the global population by the end of 2021.

show abstract

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

See 2 more Smart Citations

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A recent poll in the USA found that only 49% of Americans planned to receive a COVID-19 vaccine when available. 23 Differences in willingness to be vaccinated has also been observed across Europe. An online survey in seven European countries revealed that Germany and France had the largest proportions (10%) of the population opposed to COVID-19 vaccination; France also had the largest proportion (28%) who were unsure about receiving a vaccination.…”

Section: Monitoring Uptake Of Vaccination Programmesmentioning

confidence: 99%

Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?

Dhanda

Osborne

Lynn

et al. 2020

BMJ EBM

View full text Add to dashboard Cite

In the current era of the COVID-19 pandemic, the world has never been more interested in the process of vaccine development. While researchers across the globe race to find an effective yet safe vaccine to protect populations from the newly emergent SARS-CoV-2 virus, more than one-third of the world has been subjected to either full or partial lockdown measures. With communities having felt the burden of prolonged isolation, finding a safe and efficacious vaccine will yield direct beneficial effects on protecting against COVID-19 morbidity and mortality and help relieve the psychological and economic load on communities living with COVID-19. There is hope that with the extraordinary efforts of scientists a vaccine will become available. However, given the global public health crisis, development of a COVID-19 vaccine will need to be fast tracked through the usual prelicensing development stages and introduced with limited clinical trial data compared with those vaccines that are developed conventionally over more than a decade. In this scenario, surveillance of the vaccine in the real world becomes even more paramount. This responsibility falls to observational researchers who can provide an essential safety net by continuing to monitor the effectiveness and safety of a COVID-19 vaccine after licensing. Postauthorisation observational studies for safety and effectiveness are complementary to prelaunch clinical trials and not a replacement. In this paper, we highlight the importance of postmarketing studies for future newly licensed COVID-19 vaccines and the key epidemiological considerations.

show abstract